CardiaCare welcomes Ken Nelson as Chairman of its Board of Directors

– ISRAEL, Ness Tsiona –  CardiaCare, a clinical-stage digital therapeutic company developing the world’s first non-invasive, neuromodulation wearable for atrial fibrillation treatment, today announced the appointment of Ken Nelson as Chairman of the Board of Directors.

“We are privileged and excited to welcome Ken Nelson to CardiaCare as Chairman of the Board of DirectorsKen brings a wealth of market development, commercialization, and sales experience in the cardiac monitoring and cardiac rhythm management space. Ken joins CardiaCare as the company ramps up multiple clinical trials of our revolutionary wearable for atrial fibrillation treatment. Ken’s prior experience and success scaling cardiac device companies will be invaluable to us as we create global awareness of CardiaCare’s disruptive innovation and build out the infrastructure towards successful commercialization of our technology,” said CEO, Ofer Halbreich.

About Ken Nelson

Ken Nelson is a 20-year digital health, medical device, and remote patient monitoring executive with a stellar track record of building successful sales, marketing, and commercialization teams at Fortune 500 companies as well as startups.

Mr. Nelson spent under 10 years in sales and commercial operations leadership roles at Boston Scientific (formerly Guidant) in the Cardiac Rhythm Management division. Then, over the past 12 years, he has led retail sales and marketing efforts and has launched disruptive wearable technologies in cardiac digital health and remote patient monitoring. He played a significant role in building the teams, cultures, and infrastructures for what have become three of the top four market share players in cardiac digital health and remote patient monitoring. Most recently, he served as Head of Digital Health, Diagnostics, and Monitoring at BIOTRONIK, a global leader in the treatment of cardiac and vascular disease.

“I am pleased to join CardiaCare and look forward to working with the management team and the Board, to commercialize the first ever wearable device for closed loop, personalized, atrial fibrillation treatment, powered by artificial intelligence, that can both detect and treat atrial fibrillation non-invasively,” said Ken Nelson. “I’m impressed with the company’s revolutionary technology and the successful engagement with key opinion leaders including Mount Sinai electrophysiologist Dr. Vivek Reddy. I believe CardiaCare’s innovative solution is poised to advance patient care for the treatment of atrial fibrillation.”

About CardiaCare

CardiaCare is a clinical-stage digital therapeutic company developing the world’s first closed-loop neuromodulation wearable for non-invasive, AI-based arrhythmia care. CardiaCare was a Medtech Innovator 2022 cohort member.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.